目的 分析免疫检查点抑制剂致膀胱炎发生的特点及规律,为临床合理用药提供参考。方法 检索中国知网、万方、维普、PubMed、Web of Science数据库,收集2011年3月-2022年10月关于免疫检查点抑制剂致膀胱炎报道的文献,提取数据并进行分析。结果 共纳入15篇免疫检查点抑制剂致膀胱炎个案报道,涉及患者16例,平均年龄(56.5±8.16)岁,原发疾病为肺癌的患者最多(56.25%),膀胱炎发生时间多为用药后1~6个周期。14例经停药和(或)激素治疗后好转。结论 免疫检查点抑制剂致膀胱炎多发生在用药1~6个治疗周期后,涉及多个年龄段患者,应及时识别免疫检查点抑制剂相关性膀胱炎,尽早给予相应处理和治疗,保障患者用药安全。

Objective To analyze the characteristics and regularity of cystitis caused by immune checkpoint inhibitors, and to provide reference for clinical rational drug use. Methods The databases of CNKI, Wanfang, VIP, PubMed, and Web of Science were searched, and the literatures about cystitis caused by immune checkpoint inhibitors from March 2011 to October 2022 were collected, and the data were extracted and analyzed. Results A total of 15 case reports of cystitis caused by immune checkpoint inhibitors were included, involving 16 patients. The average age was (56.5 ± 8.16) years old, and the primary disease was lung cancer (56.25%). Cystitis usually occurs 1-6 cycles after medication. 14 cases improved after drug withdrawal and/or hormone therapy. Conclusion Cystitis caused by immune checkpoint inhibitors mostly occurs after 1-6 cycles of medication, involving patients of multiple age groups. Identify the cystitis associated with immune checkpoint inhibitors in time, give corresponding treatment and treatment as soon as possible to ensure the safety of patients’ medication.

R979.1

湖北省卫生健康委中医药科研立项项目(ZY2021Q007)